CrushSCI.com
172Average days
174.5Median days
9Fastest days
359Longest days
1,0542025 publications

Paper Review Records

All Paper Review Records

30 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

176 days

Luspatercept in Myelodysplastic Syndromes With Ring Sideroblasts: Long Term Outcome and Impact on Non‐Erythroid Blood Counts

Authors
Mara Memoli; Stefania Leone; Vincenzo Fotticchia; Simona Avilia; Novella Pugliese; Catello Califano; Maria Di Perna; Danilo De Novellis; Antonella Malandrini; Bianca Serio; Camilla Frieri; Giuseppe Gaeta; Chiara Masucci; Alessandro D'Ambrosio; Paola Della Cioppa; Giuseppe Cerciello; Tiziana Izzo; Mario Annunziata; Annamaria Maddaloni; Cono Quagliano; Giorgia Battipaglia; Marco Picardi; Francesco Grimaldi; Fabrizio PaneShow moreShow less
Affiliations
1. Department of Clinical Medicine and Surgery Hematology Division University of Naples Federico II Naples Italy; 2. Hematopoietic Stem Cell Transplantation Unit Azienda Ospedaliera A. Cardarelli Naples Italy; 3. Department of Clinical Medicine and Surgery University of Naples Federico II Naples Italy; 4. Division of Onco‐Hematology Plesso Ospedaliero Andrea Tortora Pagani Italy; 5. Department of Medicine Surgery and Dentistry Scuola Medica Salernitana University of Salerno Baronissi Italy; 6. Hematology and Transplant Center University Hospital San Giovanni Di Dio e Ruggi d’Aragona Salerno Italy; 7. Hematology and Bone Marrow Transplant Unit AORN S. Giuseppe Moscati Avellino Italy; 8. AORN S.Anna e S. Sebastiano Caserta Italy; 9. Hematology Unit Azienda Sanitaria Locale Napoli 1 Centro Naples Italy; 10. Hematology San Pio Hospital of Benevento Benevento Italy; 11. Division of Hematology AORN Cardarelli Naples Italy; 12. Section of Hematology Ospedale S. Giuliano di Giugliano Naples ItalyShow moreShow less
Source PDF DOI Publisher page
273 days

Therapeutic Approaches and Clinical Outcomes of Myeloid/Lymphoid Neoplasms With Eosinophilia Harboring FLT3 Rearrangements: A Systematic Review of 39 Cases

Authors
Peng Fang; Peng Zhang; Fan Yang; Mei Yang; Sheng Xiao; Lijun Meng; Yan ChenShow moreShow less
Affiliations
1. Department of Hematology Xiangya Hospital Central South University Changsha Hunan China; 2. National Clinical Research Center for Geriatric Diseases (Xiangya Hospital) Changsha Hunan China; 3. Hunan Hematology Oncology Clinical Medical Research Center Changsha Hunan China; 4. SANO Medical Laboratories Suzhou Sano Precision Medicine Ltd Suzhou Jiangsu China; 5. Advanced Molecular Pathology Institute of Soochow University and SANO Suzhou Jiangsu ChinaShow moreShow less
Source PDF DOI Publisher page
119 days

Temporal Trends in Real‐World Outcomes With CPX‐351 in Secondary/High‐Risk Acute Myeloid Leukemia: A PETHEMA Study

Authors
Josefina Serrano; Alicia Aguirre; David Martínez‐Cuadrón; Rosa Ayala; Juan Bergua; Julio García‐Suárez; Valle Gómez‐García de Soria; Pilar Marí; Daniel García‐Belmonte; Carmen Martínez‐Chamorro; Celina Benavente; Mayte Olave; Teresa Bernal; Eduardo Rodríguez‐Arboli; Maria‐Angeles Foncillas; Lorenzo Algarra; Juan M. Alonso; Almudena Laiglesia; Esther Prados de la Torre; Montse Arnan; Carlos Rodríguez‐Medina; Rosalía Riaza; Susana Vives; Mar Tormo; Mercedes Colorado; Jorge Labrador; Olga Salamero; Cristina Gil; Raimundo García‐Boyero; Soraya Lorente; Ana Alfonso; Olga Arce; Victor Noriega; Esperanza Lavilla; Beatriz DeRueda; Laura Torres; Joaquin Sánchez‐García; Pau Montesinos; the PETHEMA GroupShow moreShow less
Affiliations
1. Hospital Universitario Reina Sofía‐IMIBIC UCO Córdoba Spain; 2. Hospital Universitari i Politècnic La Fe Valencia Spain; 3. Hospital Universitario 12 de Octubre Universidad Complutense Madrid Madrid Spain; 4. Hospital San Pedro Alcántara Cáceres Spain; 5. Hospital Universitario Príncipe de Asturias Madrid Spain; 6. Hospital La Princesa Madrid Spain; 7. Hospital HM Madrid CIOCC Sanchinarro Madrid Spain; 8. Hospital Universitario La Zarzuela Madrid Spain; 9. Hospital Quirón‐Pozuelo Madrid Spain; 10. Hospital Clínico San Carlos Madrid Spain; 11. Hospital Universitario Lozano Blesa Zaragoza Spain; 12. Hospital Universitario Central de Asturias Oviedo Spain; 13. Instituto de Investigación del Principado de Asturias (ISPA) Oviedo Spain; 14. Instituto Universitario de Oncología del Principado de Asturias (IUOPA) Oviedo Spain; 15. Hospital Universitario Virgen del Rocío Sevilla Spain; 16. Hospital Universitario Infanta Leonor Madrid Spain; 17. Hospital General Universitario de Albacete Albacete Spain; 18. Hospital Universitario Fundación Jiménez Díaz Madrid Spain; 19. Hospital Puerta de Hierro Madrid Spain; 20. ICO H. Hospitalet Llobregat Barcelona Spain; 21. Hospital Universitario de Gran Canaria Doctor Negrín Las Palmas Spain; 22. Hospital Severo Ochoa Madrid Spain; 23. ICO Badalona‐Hospital Germans Trias i Pujol Josep Carreras Research Institute Barcelona Spain; 24. Hospital Clínico Universitario INCLIVA Biomedical Research Institute Valencia Spain; 25. Hospital Universitario Marqués de Valdecilla Santander Spain; 26. Hospital Universitario de Burgos Burgos Spain; 27. Hospital Universitario Vall D'Hebron Barcelona Spain; 28. Hospital General de Alicante Alicante Spain; 29. Hospital General Universitario de Castellón Castellón Spain; 30. Hospital Vithas Xanit Internacional Benalmádena Spain; 31. Clínica Universitaria de Navarra Pamplona Spain; 32. Hospital de Basurto Bilbao Spain; 33. Complejo Hospitalario Universitario A Coruña A Coruña Spain; 34. Hospital Universitario Lucus Augusti Lugo Spain; 35. Hospital Miguel Servet Zaragoza Spain; 36. Departament de Medicina Universitat de València Valencia SpainShow moreShow less
Source PDF DOI Publisher page
198 days

The Histone Lactylation of KREMEN2 Inhibits Ferroptosis Through the JAK2/STAT3/GPX4 Axis and Promotes the Progression of Mantle Cell Lymphoma

Authors
Shujun Li; Jingmin Luo; Wenjia Wei; Haiyue SunShow moreShow less
Affiliations
1. Department of Hematology Xiangya Hospital Central South University Changsha China; 2. National Clinical Research Center for Geriatric Diseases (Xiangya Hospital, Central South University) Changsha China; 3. Hunan Hematology Oncology Clinical Medical Research Center Changsha China; 4. Xiangya School of Medicine Central South University Changsha ChinaShow moreShow less
Source PDF DOI Publisher page
183 days

Baseline Spleen Volume is Independently Associated With Survival After CD19‐Directed Chimeric Antigen Receptor T‐Cell Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma

Authors
Lucas Brehm; Philipp Schindler; Christian Römer; Akhil Behringer; Valeria Carobin; Georg Evers; Cyrus Khandanpour; Julia Marx; Christian Reicherts; Jörn Albring; Matthias Stelljes; Evgenii Shumilov; Georg Lenz; Alexander PohlmannShow moreShow less
Affiliations
1. Department of Medicine A University Hospital Münster Münster Germany; 2. Department of Radiology University Hospital Münster Münster Germany; 3. Department of Oncology and Hematology University Hospital Oldenburg Oldenburg GermanyShow moreShow less
Source PDF DOI Publisher page
47 days

Adjusted Indirect Comparison Between Epcoritamab‐R 2 and Tafasitamab‐R 2 in Relapse/Refractory Follicular Lymphoma

Authors
Leonidas Benetatos; Elisavet Apostolidou; Vasileios Georgoulis; Georgios S. Markopoulos; Savvas Dimitriadis; Eleftheria Hatzimichael; Eleni KapsaliShow moreShow less
Affiliations
1. Department of Ηematology Faculty of Medicine School of Health Sciences University of Ioannina Ioannina Greece; 2. Department of Physiology Faculty of Medicine School of Health Sciences University of Ioannina Ioannina Greece; 3. Hematology Laboratory Unit of Molecular Biology and Translational Flow Cytometry University Hospital of Ioannina Ioannina GreeceShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does HEMATOLOGICAL ONCOLOGY take to review a manuscript?

As of 2026-11-17, CrushSCI has 30 complete review records for HEMATOLOGICAL ONCOLOGY. The fastest paper went from submission to acceptance in 9 days (Characterization of Adverse Cutaneous Effects in the Setting of Ponatinib, Bosutinib, and Asciminib for Chronic Myeloid Leukemia Patients, received 2026-09-30, accepted 2026-10-09); the slowest took 359 days. The average is 172 days and the median is 174.5 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.